This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction

< Back

Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction


Cardiovascular Disease and Vascular Surgery

November 2020

Omecamtiv mecarbil is currently in clinical development for the treatment of heart failure (HF) with reduced ejection fraction. HF is a complex clinical syndrome of symptoms and signs that suggest the efficiency of the heart to pump blood around the body is impaired. The classic symptoms of HF are breathlessness, ankle swelling, or fatigue. More than half of people with HF have reduced ejection fraction (HFrEF) which means the heart muscle does not contract effectively and therefore less oxygen-rich blood is pumped out to the body. There remains a large unmet need for new therapies in the treatment of HFrEF.
Omecamtiv mecarbil is given by oral administration in the form of a tablet. Omecamtiv mecarbil works by interacting with a protein called cardiac myosin that is responsible for converting chemical energy into the mechanical force that results in contraction of the heart. The interaction of omecamtiv mecarbil with cardiac myosin improves the performance of the heart muscle to preserve its function. If licensed, omecamtiv mecarbil may provide an additional treatment option for people with HFrEF who currently have limited therapies available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts